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Background: Surgical-site infections (SSIs) increase patient morbidity and costs. The aim was to identify
and synthesize all RCTs evaluating the effect of topical antibiotics on SSI in wounds healing by primary
intention.
Methods: The search included Ovid MEDLINE, Ovid Embase, the Cochrane Wounds Specialized
Register, Central Register of Controlled Trials and EBSCOCINAHL from inception toMay 2016. There
was no restriction of language, date or setting. Two authors independently selected studies, extracted data
and assessed risk of bias. When sufficient numbers of comparable trials were available, data were pooled
in meta-analysis.
Results: Fourteen RCTs with 6466 participants met the inclusion criteria. Pooling of eight trials (5427
participants) showed that topical antibiotics probably reduced the risk of SSI compared with no topical
antibiotic (risk ratio (RR) 0⋅61, 95 per cent c.i. 0⋅42 to 0⋅87; moderate-quality evidence), equating to
20 fewer SSIs per 1000 patients treated. Pooling of three trials (3012 participants) for risk of allergic
contact dermatitis found no clear difference between antibiotics and no antibiotic (RR 3⋅94, 0⋅46 to
34⋅00; very low-quality evidence). Pooling of five trials (1299 participants) indicated that topical antibiotics
probably reduce the risk of SSI compared with topical antiseptics (RR 0⋅49, 0⋅30 to 0⋅80; moderate-quality
evidence); 43 fewer SSIs per 1000 patients treated. Pooling of two trials (541 participants) showed no clear
difference in the risk of allergic contact dermatitis with antibiotics or antiseptic agents (RR 0⋅97, 0⋅52 to
1⋅82; very low-quality evidence).
Conclusion: Topical antibiotics probably prevent SSI compared with no topical antibiotic or antiseptic.
No conclusion can be drawn regarding whether they cause allergic contact dermatitis.
This paper is based on a Cochrane Review: Heal CF, Banks JL, Lepper PD, Kontopantelis E, van Driel ML. Topical
antibiotics for preventing surgical site infection in wounds healing by primary intention. Cochrane Database Syst Rev
2016; (11)CD011426.
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Introduction
Many surgical procedures are performed every year; the
majority result in wounds that heal by primary intention.
Surgical-site infections (SSIs) account for up to 20 per cent
of all of healthcare-associated infections1. At least 5 per
cent of patients who have a surgical procedure will develop
an SSI2. SSIs can delay healing, impair cosmetic outcomes
and potentially cause other morbidity, such as deeper infec-
tions, as well as increase costs and the consumption of
healthcare resources3.
The acceptable rate of SSI following clean surgery (class
1) is less than 5 per cent4,5, although some patients and
procedures are at higher risk. Therefore, oral antibiotic
prophylaxis of clean surgical wounds is usually reserved for
at-risk patients or high-risk procedures3,6,7. Although lim-
ited guidelines exist for the use of oral antibiotics as infec-
tion prophylaxis, there is no guidance on the prophylactic
use of topical antibiotics.
The only information available on the frequency of
topical antibiotic use on wounds is a survey of plastic
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surgeons in the UK, which revealed that 66 per cent used
chloramphenicol eye ointment in their practice8,9.
Adverse effects include allergic contact dermatitis, ana-
phylaxis and antibiotic resistance10–12.
There is little evidence in the literature regarding the effi-
cacy of antibiotic ointment in preventing SSI, and some
existing evidence is conflicting. A systematic review of trials
is important to guide clinical practice. The authors con-
ducted a Cochrane Review13, which is summarized in this
article. Better information on efficacy could assist in ratio-
nalizing use and contribute to controlling development of
antibiotic resistance in the community. The primary aim
of this review was to determine whether the application of
topical antibiotics after primary closure reduces the inci-
dence of SSI.
Methods
Criteria for considering studies for this review
All RCTs or quasi-randomized trials examining surgical
wounds healing by primary intention were included. There
was no limitation for age, sex, country of origin or surgi-
cal setting. Secondarily infected wounds, wounds healing
by secondary intention and the application of prophy-
laxis before closure were excluded. Ointments, creams,
lotions, solutions, gels, tinctures, foams, pastes, powders
and impregnated dressings were included in the definition
of topical antibiotic, but not silver or antiseptics. Excluded
were antibiotic irrigation or washouts, subcutaneous infil-
tration of the antibiotic, any topical treatment applied
before closure by primary intention and antibiotic-coated
sutures. The topical antibiotic may have been applied with,
or without a dressing. The comparison group was topical
antiseptic or no treatment.
The primary outcomewas SSI, as defined by theUSCen-
ters for Disease Control and Prevention. In this definition,
infection must occur within 30 days of the procedure, so
this time point was used as a cut-off for this primary out-
come measure. The trial authors’ definitions of infection
were accepted. Adverse effects within 30 days of the pro-
cedure were also a primary outcome, and were defined as
allergic contact dermatitis, anaphylaxis or infections with
patterns of antibiotic resistance.
Literature search
The following electronic databases were searched to
identify reports of relevant RCTs from inception to
May 2016: the Cochrane Wounds Specialized Register
(searched 12 May 2016); Ovid MEDLINE; Ovid MED-
LINE (In-Process & Other Non-Indexed Citations); Ovid
Embase; the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library); and EBSCO
Cumulative Index to Nursing and Allied Health Literature
(CINAHL). The Ovid MEDLINE search was combined
with the Cochrane Highly Sensitive Search Strategy for
identifying randomized trials in MEDLINE: sensitivity-
and precision-maximizing version (2008 revision)14. The
Embase search was combined with the Ovid Embase filter
developed by the UK Cochrane Centre14. The CINAHL
searches were combined with the trial filters developed by
the Scottish Intercollegiate Guidelines Network15. Studies
were not restricted with respect to language or date of
publication.
Clinical trials registries and bibliographies of all retrieved
and relevant publications identified were searched for addi-
tional eligible trials, andmanufacturers and pharmaceutical
companies contacted regarding studies for inclusion.
Data extraction
Two review authors screened the titles and abstracts
independently. They obtained a copy of the full article
for potentially eligible studies. Any discrepancies were
resolved by consensus discussion with a third author.
Where necessary and possible, additional information
was sought from the principal investigator of the trial
concerned.
The following data were extracted: eligibility criteria,
trial characteristics, methods, participants, intervention,
control group, outcome definitions and outcome data for
primary and secondary outcomes, and key conclusions of
study authors.
Assessment of risk of bias in included studies
Two review authors independently assessed each included
study for risk of bias (selection bias, performance bias and
attrition bias)16. A threshold was set such that trials assessed
as at risk of either random number generation, allocation
concealment or assessor blinding were considered to be at
high risk of bias. If missing outcome data were distributed
unequally over the intervention arms, the study was
deemed to be at high risk of attrition bias, and the authors
considered performing an intention-to-treat analysis.
Statistical analysis
All outcomes measured in the review were dichotomous.
Risk ratio (RR) was used as the effect measure, with 95
per cent c.i. I2 was interpreted according to the Cochrane
Handbook14, taking into account factors such as overlap
of confidence intervals, and whether heterogeneity was in
the magnitude or in the direction of the effect. Where
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Records identified through
database searching
n = 763
Additional records identified
through other sources
n = 3
Records screened after duplicates removed
n = 763
Records excluded (not relevant
to topic or not an RCT)
n = 697
Full-text articles assessed
for eligibility
n = 66
Full-text articles excluded n = 52
 Antibiotics before wound closure n = 26
 Not healed by primary intention n = 14
 Not topical antibiotic n = 8
 Topical antibiotic to a catheter, not sutured wound n = 2
 Wound already infected n = 1
 Book club report of RCT n = 1Studies included in
qualitative synthesis
n = 14*
Studies included in
quantitative synthesis
(meta-analysis)
n = 11
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Fig. 1 PRISMA diagram for the systematic review. *Two of the 14 studies did not record the outcome of surgical-site infection (SSI),
and one did not have extractable data for the outcome of SSI. All three of these studies were used in the meta-analysis of the outcome of
wound healing, which is not presented in this abridged version of the original Cochrane Review13
levels of clinical and statistical heterogeneity permitted,
the data were pooled in a meta-analysis using Review
Manager 5.1 software (The Cochrane Collaboration, The
Nordic Cochrane Centre, Copenhagen, Denmark) with a
random-effects model. Absolute risk differences were also
calculated in order to determine the number needed to
treat (NNTT). When insufficient data were available for
meta-analyses, a narrative synthesis of the outcome across
the included studies was presented.
The expected rate of SSI is 1–10 per cent. If missing ran-
domized participants were assumed to indicate treatment
failure (they had developed an infection), the rate of SSI
would be increased falsely in the intervention group. As
included trials had either complete data or minimal missing
data, which was balanced over the intervention and con-
trol groups, complete case analysis was done for all trials
in the review, recognizing the issue of trials with miss-
ing data when determining attrition bias in the risk-of-bias
assessment.
If there were three or four arms in a study, where two or
three of the arms were clinically similar for the purposes of
the review, they were combined to create a single pairwise
comparison. Where they could not be combined, multiple
arms were included in the same analysis, but total results
were not calculated in these tables.
One study16 assessed multiple wounds per patient; ran-
domization was at the level of the patient but the unit of
analysis was the wound. The present authors could not
find a published standard value for an inter-cluster correla-
tion (ICC) for this scenario, so explored potential situations
with different values used for ICC, and performed a sensi-
tivity analysis on the overall effect. If the ICC was 1⋅0, as
opposed to no adjustment for clustering, the RR did not
change by a substantial amount, so no further adjustment
was made.
Sensitivity analysis was done to assess the impact of risk
of bias on the overall effect.
Results
The results of the search are shown in a PRISMA flow
diagram (Fig. 1). The search identified 763 studies of poten-
tial relevance. After the first screening, 66 citations were
considered potentially relevant. A total of ten RCTs and
four quasi-randomized trials with 6466 participantsmet the
inclusion criteria. Their study characteristics are shown in
Table 116–28.
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Table 1 Characteristics of included studies
Reference Country
Setting and type
of surgery Interventions* SSI
Allergic contact
dermatitis
Caro et al.17† UK Emergency department;
superficial lacerations
A: Neomycin–polymixin B–bacitracin
aerosol (197)
A: 18 of 197 n.s.
B: No treatment (235)* B: 27 of 235
?500 patients randomized (unclear) Unclear whether
missing cases
Dire et al.18 USA Emergency department;
lacerations
A: Bacitracin zinc ointment (109) A: 6 of 109 A: 0 of 109
B: Neomycin sulfate, bacitracin zinc,
polymixin B ointment (110)
B: 5 of 110 B: 1 of 110
C: Silver sulfadiazine cream 1% (99) C: 12 of 99 C: 0 of 99
D: Petroleum ointment (108) D: 19 of 108 D: 0 of 108
465 patients randomized 39 lost to follow-up
(allocation not
specified)
Dixon et al.16 Australia General practice skin
cancer clinic;
dermatological surgery
A: Mupirocin ointment 20mg/g (262
patients; 562 wounds)
A: 13 of 562 A: 0 of 562
B: Paraffin ointment (269 patients; 729
wounds)
B: 12 of 729 B: 0 of 729
C: No ointment (247 patients; 510) C: 7 of 510 C: 0 of 510
wounds No missing cases
Gilmore and Welbourn19 UK General hospital setting;
appendicectomy
A: Neomycin–bacitracin–polymixin B
aerosol (84)
A: 8 of 84 n.s.
B: 5% povidone–iodine aerosol (84) B: 7 of 84
C: Control (no aerosol) (84) C: 15 of 84
No missing cases
Gough and Lawton20 (1)† UK Children’s hospital;
circumcision
A: Soframycin-impregnated tulle gras
(54)
n.s. n.s.
B: Benzoin compound-soaked gauze
(54)
Gough et al.20 (2)† UK Children’s hospital;
circumcision
A: Soframycin-impregnated tulle gras
(105)
n.s. n.s.
B: Paraffin tulle dressing (105)
Heal et al.21 Australia General practice; minor
skin excisions
A: Chloromycetin ointment 1% (509) A: 32 of 488 n.s.
B: Paraffin ointment (505) B: 53 of 484
Hood et al.22 USA Emergency department;
uncomplicated soft
tissue wounds
A: Bactroban (mupirocin) cream 2% A: 2 of 50 n.s.
B: Neosporin cream
(neomycin–polymixin–bacitracin
3⋅5mg/10 000 units/400 units)
B: 0 of 49
120 total randomized 99 total; 21 lost to
follow-up (allocation
not specified)
Iselin et al.23† France Hospital inpatient and
outpatient departments;
hand surgery
A: Soaked pad of rifampicin (134?) A: 8 of 114 A: 16 of 114
B: Soaked pad of iodinated
polyvidone solution (134)
B: 20 of 109 B: 16 of 109
Kamath et al.24 UK Orthopaedic department;
hip surgery
A: Chloramphencicol 1% ointment
(50)
A: 4 of 47 n.s.
B: No ointment (50) B: 8 of 45
Khalighi et al.25 USA Hospital; cardiac implant
insertions
A: Neomycin ointment 3⋅5mg/g (263) A: 2 of 263 n.s.
B: Standard dressing (248) B: 4 of 248
C: Povidone–iodine ointment 10%
(257)
C: 4 of 257
D: Sterile non-adherent dressing (240) D: 4 of 240
Neri et al.26† Italy Hospital surgical ward;
laparoscopic
cholecystectomy
A: 3ml rifampicin ointment (24) Infection listed as
outcome, but data
could not be
extracted
n.s.
B: No ointment (24)
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Table 1 Continued
Reference Country
Setting and type
of surgery Interventions* SSI
Allergic contact
dermatitis
Pradhan and
Agrawal27
Nepal Hospital; emergency
caesarean section
A: Fusidic acid 2% (35) A: 1 of 35 n.s.
B: No ointment (35) B: 6 of 35
No missing cases
Smack et al.28 USA Outpatient dermatology clinic;
dermatological surgery
A: Bacitracin ointment 500 units/g A: 4 of 444 patients,
597 wounds
A: 4 of 444
B: Petrolatum ointment B: 9 of 440 patients,
610 wounds
B: 0 of 440
922 patients randomized with 1249 wounds;
unclear whether 38 missing patients
allocated to intervention or control
*Values in parentheses are number of patients randomized. †Quasi-randomized study. SSI, surgical-site infection; n.s., not stated.
Ten two-arm studies were included, two three-arm
studies16,19 and two four-arm studies18,25. In all of the
three- and four-arm trials, the intervention groups were
considered to be receiving separate interventions and so
all relevant comparisons were included.
Six studies16–18,21,22,28 involved minor procedures that
were all conducted in an outpatient or emergency depart-
ment setting. Eight trials19,20,23–27 involved general
surgery performed in an operating theatre.
The surgical procedures in each trial were classi-
fied as clean3,16,21,28, clean-contaminated7,19,20,24–27 or
contaminated4,17,18,22,23; there were no dirty procedures.
Eight trials compared topical antibiotics with no topi-
cal antibiotics, and six compared topical antibiotics with
topical antiseptics. Three of these trials had multiple arms
comparing topical antibiotics with both antiseptics and no
treatment.
Risk of bias in included studies
In total, seven16,17,19,20,23,26 of the 14 included trials were
deemed to be at high risk of bias.
There were no trials in which participants were excluded
from the analysis in sufficient numbers to cause potential
bias. The dropout rate was no greater than 15 per cent in
any trial, and numbers of dropouts were balanced between
intervention and control groups when group allocation was
recorded.
Two studies19,22 reported pharmaceutical sponsorship
from companies that supplied one or more of the study
agents.
Effects of interventions: prevention of surgical-site
infection
Of the 14 trials included in the review, only 11 reported
SSI as an outcome. In one of these trials26, the data for SSI
were not extractable. This study was not included in data
pooling for this outcome.
Topical antibiotic versus no topical antibiotic
Eight trials (5427 participants) were pooled to compare
the effects of topical antibiotics with no topical antibiotics
on SSI (Fig. 2). There were fewer infections with topical
antibiotics than without (RR 0⋅61, 95 per cent c.i. 0⋅42 to
0⋅87). There was an absolute risk difference of 20 fewer
SSIs per 1000 patients, and the number needed to benefit
(NNTB) with topical antibiotic in order to avoid one
additional SSI was 50. Most of these eight studies were at
low or unclear risk of bias, and the quality of the evidence
for this outcome was moderate. There was moderate
interstudy heterogeneity (I2 = 44 per cent).
The effect estimate was robust to removal of studies at
high risk of bias (RR 0⋅49, 0⋅35 to 0⋅67; 3026 participants,
5 studies; I2 = 0 per cent).
Pooling of three trials (3012 participants) that provided
data on the risk of allergic contact dermatitis showed no dif-
ference (RR 3⋅94, 0⋅46 to 34⋅00; very low-quality evidence)
(Fig. S1, supporting information).
There were no trials reporting anaphylaxis or patterns of
antibiotic resistance.
Topical antibiotic versus topical antiseptic
In the pooling of five trials (1299 participants), topi-
cal antibiotics reduced the risk of SSI compared with
topical antiseptics (RR 0⋅49, 95 per cent c.i. 0⋅30 to
0⋅80; moderate-quality evidence) (Fig. 3). This difference
reflected an absolute difference in risk of 43 fewer cases of
SSI per 1000 people treated with topical antibiotics rather
than antiseptics (95 per cent c.i. 17 to 59 fewer per 1000;
NNTB 24). There was minor interstudy heterogeneity
(I2 = 12 per cent).
The overall effect was robust to removal of studies
at high risk of bias (RR 0⋅39, 0⋅20 to 0⋅76; 908 partici-
pants, 3 studies), and heterogeneity was reduced (I2 = 0
per cent).
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SSI
Topical antibiotic
Caro et al.17
Dire et al.18*
Dixon et al.16†
Gilmore and Welbourn19‡
Heal et al.21
Kamath et al.24
Khalighi et al.25§
Smack et al.28
18 of 197
11 of 219
13 of 562
8 of 84
32 of 488
4 of 47
2 of 263
4 of 444
92 of 2304
27 of 235
19 of 108
19 of 1239
15 of 84
53 of 484
8 of 45
8 of 488
9 of 440
158 of 3123
17·6
14·2
14·4
12·2
21·9
7·7
4·7
7·3
100·0
0·80 (0·45, 1·40)
0·29 (0·14, 0·58)
1·51 (0·75, 3·03)
0·53 (0·24, 1·19)
0·60 (0·39, 0·91)
0·48 (0·15, 1·48)
0·46 (0·10, 2·17)
0·44 (0·14, 1·42)
0·61 (0·42, 0·87)Total
Total events
Heterogeneity: τ2 = 0·11; χ2 = 12·43, 7 d.f., P = 0·09; I2 = 44%
Test for overall effect: Z = 2·72, P = 0·006
Reference No topical antibiotic Weight (%)
0·01 0·1
Favours antibiotic Favours no antibiotic
1 10 100
Risk ratio Risk ratio
Fig. 2 Forest plot comparing the effects of topical antibiotics versus no topical antibiotic on surgical-site infection (SSI). A
Mantel–Haenszel random-effects model was used for meta-analysis. Risk ratios are shown with 95 per cent confidence intervals.
*Three of the four study arms are used here; the two antibiotic arms were combined and compared with the inert control arm. †There
were two no-treatment arms in this three-arm study; this comparison is mupirocin versus combined petroleum and no ointment. ‡Two
of the three study arms are used here: topical antibiotic versus no-treatment control. §Three of the four study arms are used here:
neomycin versus combined non-adherent dressing and standard dressing
SSI
Topical antibiotic
Dire et al.18*
Gilmore and Welbourn19†
Khalighi et al.25‡
11 of 219
8 of 84
2 of 263
30 of 715
12 of 99
7 of 84
4 of 257
49 of 584
31·8
22·4
8·1
100·0
0·41 (0·19, 0·91)
1·14 (0·43, 3·01)
0·49 (0·09, 2·64)
Pradhan and Agrawal27 1 of 35 6 of 35 5·5 0·17 (0·02, 1·31)
Iselin et al.23 8 of 114 20 of 109 32·2 0·38 (0·18, 0·83)
0·49 (0·30, 0·80)Total
Total events
Heterogeneity: τ2 = 0·04; χ2 = 4·56, 4 d.f., P = 0·33; I2 = 12%
Test for overall effect: Z = 2·84, P = 0·005
Reference Antiseptic Weight (%)
0·01 0·1
Favours antibiotic Favours antiseptic
1 10 100
Risk ratio Risk ratio
Fig. 3 Forest plot comparing the effects of topical antibiotics versus topical antiseptics on surgical-site infection (SSI). A
Mantel–Haenszel random-effects model was used for meta-analysis. Risk ratios are shown with 95 per cent confidence intervals.
*There were two antibiotic arms (bacitracin and neomycin), an antiseptic arm (silver) and an inert vehicle control arm (petroleum) in
this four-arm study; this comparison is the two combined antibiotic arms versus the antiseptic arm. †Two of the three study arms are
used here: topical antibiotic experimental versus antiseptic control arm. ‡Two of the four study arms are used here: neomycin versus
povidone–iodine ointment
Pooling of two trials (541 participants) showed no clear
difference in the risk of allergic contact dermatitis with
topical antibiotics compared with antiseptics (RR 0⋅97,
0⋅52 to 1⋅82; very low-quality evidence) (Fig. S2, supporting
information).
There were no trials reporting anaphylaxis or patterns of
antibiotic resistance.
Discussion
This systematic review andmeta-analysis found that topical
antibiotics applied to surgical wounds healing by primary
intention reduced the risk of SSI, whether compared with
no antibiotic or no topical antiseptic (moderate-quality
evidence). In clean (class 1) surgery, where the baseline
infection rate is already low, the absolute risk reduction
in SSI is probably smaller, and the case for use of topical
antibiotics weaker.
It was not possible to draw conclusions regarding the
effects of topical antibiotics on allergic contact dermatitis
owing to lack of statistical power (small sample sizes). Any
use of topical antibiotic needs to be tempered by consider-
ation of side-effects such as allergic contact dermatitis, and
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the evidence for this outcome, while critical, was found to
be of very low quality. There were no patterns of antibiotic
resistance or anaphylaxis in any of the studies identified.
Subgroup analysis was not possible owing to lack of suffi-
cient study numbers.
Some studies16,25,28 had very low baseline rates of infec-
tion of around 2 per cent; for all other trials baseline rates
were 10–20 per cent. In several of the studies19,21,27 this
baseline infection rate was higher than is considered to
be acceptable29, and this may limit the applicability of the
evidence. The mean absolute risk reduction was 4⋅3 per
cent when compared with antiseptics, and 2 per cent when
compared with no treatment, but this result was hetero-
geneous in both comparisons and much lower in studies
with low baseline infection rates. Two of the three studies
with low baseline infection rates involved class 1 wounds.
The baseline results in these studies and the results of the
meta-analysis raise the question of whether prophylaxis is
necessary in populations with clean class 1 wounds. The
NNTT for an additional beneficial outcome was 24 in the
antiseptic comparator group and 50 in the no-treatment
comparator group, but again would be much higher in sit-
uations where the baseline infection rate was low.
RCTs need to be adequately powered so that they are
able to detect treatment effects of a specified size, should
they exist. As the incidence of SSI is often low, an ade-
quate number of patients need to be recruited to detect
a clinically significant difference. Only three of the trials
reported sample size calculations. One study16 was under-
powered because the baseline incidence of SSI was lower
than that expected when the sample size was calculated.
Some authors inappropriately reported topical antibiotics
to be ineffective, rather than acknowledging that their
study was underpowered.
In the existing published literature there was one
editorial30, two literature reviews31,32 and three systematic
reviews33–35 that, in all but one case, concluded that there
was little evidence for the efficacy of topical antibiotics to
prevent SSI, particularly after dermatological surgery. One
study35 pooled data from four studies comparing topical
antibiotics with petroleum/paraffin for dermatological
procedures, and favoured topical antibiotics (pooled odds
ratio 0⋅71, 95 per cent c.i. 0⋅42 to 0⋅19). Guidelines2,14 rec-
ommend that antibiotic prophylaxis, not limited to topical
antibiotics, is not required for clean minor surgical proce-
dures. National Institute for Health and Care Excellence
(NICE) guidelines also state: ‘do not use topical antibiotics
in wounds healing by primary intention to reduce the
risk of surgical site infection’2. The present review has
contributed additional evidence, although practice must
be guided by clinical judgement of risks and benefits.
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